Novel ligands for the investigation of imidazoline receptors and their binding proteins

被引:22
作者
Hudson, AL [1 ]
Tyacke, RJ
Lalies, MD
Davies, N
Finn, DP
Martí, O
Robinson, E
Husbands, S
Minchin, MCW
Kimura, A
Nutt, DJ
机构
[1] Univ Bristol, Sch Med Sci, Psychopharmacol Unit, Bristol BS8 1TD, Avon, England
[2] Yamanouchi Res UK, Surrey KT14 6RA, England
[3] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
[4] Univ Autonoma Barcelona, Dept Biol Cellular Fisiol & Immunol, Unitat Fisiol Anim, E-08193 Barcelona, Spain
来源
AGMATINE AND IMIDAZOLINES: THEIR NOVEL RECEPTORS AND ENZYMES | 2003年 / 1009卷
关键词
imidazoline receptors; BU224; 2BFI; imidazoline binding sites; creatine kinase;
D O I
10.1196/annals.1304.039
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
New ligands for imidazoline receptors are described so that these receptors can be more fully explored and understood. BU224, (2-(4,5-dihydroimidaz-2-yl)-quinoline, shows high affinity and is selective for the imidazoline-2 (I-2) class of receptors. BU224 was tested in the rat Porsolt forced swim paradigm where it was found to decrease time spent immobile and increase the time spent swimming, consistent with an antidepressant profile. BU224 was tritiated and, in radioligand binding studies, was found to label a single population of saturable sites with high affinity. In vitro brain autoradiography with [H-3]BU224 also showed a pattern of distribution similar to the known labeling of I-2 receptors. A new series of four 2BFI (2-(benzofuranyl)-2-imidazoline) derivatives were investigated as potential ligands for imaging brain I-2 receptors using positron emission tomography (PET). At least two, BU20012 and BU20013, retained high affinity and moderate selectivity and penetrated the brain when administered peripherally in the mouse. 2BFI has undergone the Mannich reaction to immobilized diaminodipropyl amine to fabricate an affinity column, which was used to isolate a protein from rabbit brain; this protein was sequenced and identified as the enzyme creatine kinase.
引用
收藏
页码:302 / 308
页数:7
相关论文
共 8 条
[1]   'Seeing through a glass darkly': casting light on imidazoline 'I' sites [J].
Eglen, RM ;
Hudson, AL ;
Kendall, DA ;
Nutt, DJ ;
Morgan, NG ;
Wilson, VG ;
Dillon, MP .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (09) :381-390
[2]   Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test [J].
Finn, DP ;
Martí, O ;
Harbuz, MS ;
Vallès, A ;
Belda, X ;
Márquez, C ;
Jessop, DS ;
Lalies, MD ;
Armario, A ;
Nutt, DJ ;
Hudson, AL .
PSYCHOPHARMACOLOGY, 2003, 167 (02) :195-202
[3]   Imidazoline receptors and human brain disorders [J].
García-Sevilla, JA ;
Escribá, PV ;
Guimón, J .
IMIDAZOLINE RECEPTORS AND THEIR ENDOGENOUS LIGANDS: CURRENT CONCEPTS AND THERAPEUTIC POTENTIAL, 1999, 881 :392-409
[4]   Novel selective compounds for the investigation of imidazoline receptors [J].
Hudson, AL ;
Gough, R ;
Tyacke, R ;
Lione, L ;
Lalies, M ;
Lewis, J ;
Husbands, S ;
Knight, P ;
Murray, F ;
Hutson, P ;
Nutt, DJ .
IMIDAZOLINE RECEPTORS AND THEIR ENDOGENOUS LIGANDS: CURRENT CONCEPTS AND THERAPEUTIC POTENTIAL, 1999, 881 :81-91
[5]  
HUDSON AL, 2001, PHARM NEWS, V8, P18
[6]   Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands [J].
Lalies, MD ;
Hibell, A ;
Hudson, AL ;
Nutt, DJ .
IMIDAZOLINE RECEPTORS AND THEIR ENDOGENOUS LIGANDS: CURRENT CONCEPTS AND THERAPEUTIC POTENTIAL, 1999, 881 :114-117
[7]  
Nutt D J, 1995, Ann N Y Acad Sci, V763, P125, DOI 10.1111/j.1749-6632.1995.tb32397.x
[8]   Distribution of [3H]BU224, a selective imidazoline I2 binding site ligand, in rat brain [J].
Robinson, ESJ ;
Tyacke, RJ ;
Nutt, DJ ;
Hudson, AL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 450 (01) :55-60